Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.

Author: AmaraAlieu, BisdominiElisa, BoffitoMarta, CerroneMaddalena, ChallengerElizabeth, ElliotEmilie R, ElseLaura, KhooSaye, OwenAndrew

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolutegravir and darunavir, when boosted with cobicistat, can be safely prescribed together for the treatment of HIV-1 without dosage adjustments.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Dolutegravir combined with darunavir/cobicistat is a promising NRTI-sparing and/or salvage strategy for the treatment of HIV-1 infection. METHODS: This Phase I, open-label, 57 day, crossover, pharmacokinetic (PK) study, enrolled healthy volunteers aged 18-65 years, who were randomized t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/jac/dky384

データ提供：米国国立医学図書館（NLM）

Pharmacokinetics of Dolutegravir with and without Darunavir/Cobicistat

In the world of medicine, we constantly strive to find the perfect balance, much like a camel navigating a desert, seeking the optimal path. This research investigates the pharmacokinetics of dolutegravir, an antiretroviral drug used to treat HIV-1 infection. The authors explored the impact of co-administering dolutegravir with darunavir/cobicistat, a combination therapy known to enhance the effectiveness of HIV-1 treatment. Their findings provide valuable insights into the pharmacokinetic interactions of these drugs, guiding the development of effective treatment regimens.

Dolutegravir and Darunavir/Cobicistat: A Compatible Combination?

The study found that co-administering dolutegravir with darunavir/cobicistat did not significantly alter the pharmacokinetic profile of either drug. This suggests that the combination therapy can be safely prescribed without requiring dosage adjustments. This research provides valuable data for clinicians, enabling them to develop effective and well-tolerated treatment regimens for HIV-1 infection. The results are a testament to the careful research and development that underpin effective treatment strategies.

Implications for HIV-1 Treatment and Drug Development

This research underscores the importance of carefully evaluating drug interactions and pharmacokinetic profiles in developing effective treatment regimens. The study's findings provide valuable data for clinicians, enabling them to prescribe dolutegravir and darunavir/cobicistat with confidence. This research contributes to the ongoing quest for innovative and safe therapies for HIV-1 infection, a challenging journey that demands careful consideration of drug interactions and patient safety.

Dr.Camel's Conclusion

This research offers valuable insights into the pharmacokinetic compatibility of dolutegravir and darunavir/cobicistat. The study's findings are a beacon of hope for patients with HIV-1, indicating a safe and effective combination therapy. As researchers, we continue to explore the vast desert of medicine, seeking new oases of knowledge to improve patient outcomes.

Date :
  1. Date Completed 2020-01-14
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

30272231

DOI: Digital Object Identifier

10.1093/jac/dky384

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.